Facebook
Twitter
Telegram
Report an ErrorArcadia Biosciences Balance Sheet 2011-2024 | RKDA
Annual Balance Sheet Arcadia Biosciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-5.51 M | -18.6 M | -25.4 M | -10.8 M | -8.29 M | -12 M | -9.12 M | 71.7 M | 27.2 M | -2.1 M | 11.7 M | 2.65 M | - |
Long Term Debt |
155 K | 1.01 M | 2.22 M | 2.1 M | 107 K | - | - | 25.1 M | 24.9 M | 8.87 M | 9.92 M | 8 M | - |
Long Term Debt Current |
852 K | 1.01 M | 1.07 M | 717 K | 611 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 12.5 M | 18.5 M | 8.16 M | 5.04 M | 31.2 M | 30.6 M | 15.5 M | 17.3 M | 15.7 M | - |
Total Current Liabilities |
3.59 M | 4.21 M | 5.04 M | 6.31 M | 5.71 M | 3.05 M | 3.52 M | 3.13 M | 3.45 M | - | - | - | - |
Total Liabilities |
7 M | 8.02 M | 12.7 M | 18.8 M | 24.2 M | 11.2 M | 8.56 M | 34.4 M | 34 M | 26.8 M | 26.8 M | 19 M | - |
Deferred Revenue |
- | - | - | 8 K | 42 K | 96 K | 1 M | 740 K | 1.01 M | 830 K | 1.07 M | 1.16 M | - |
Retained Earnings |
-272 M | -258 M | -226 M | -212 M | -207 M | -178 M | -167 M | -152 M | -132 M | -114 M | -95.6 M | -82.4 M | - |
Total Assets |
19.7 M | 28.9 M | 43.9 M | 47.3 M | 32.6 M | 24 M | 16.6 M | 56.6 M | 74.2 M | 24.9 M | 9.54 M | 13.4 M | - |
Cash and Cash Equivalents |
6.52 M | 20.6 M | 28.7 M | 14 M | 8.42 M | 12 M | 9.12 M | 2.01 M | 24 M | 16.6 M | - | - | - |
Book Value |
12.7 M | 20.9 M | 31.2 M | 28.6 M | 8.33 M | 12.8 M | 8.01 M | 22.2 M | 40.2 M | -1.88 M | -17.3 M | -5.68 M | - |
Total Shareholders Equity |
12.8 M | 21 M | 31.1 M | 27.7 M | 7.7 M | 12.8 M | 8.01 M | 22.2 M | 40.2 M | -84.8 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Arcadia Biosciences
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
21 K | 155 K | 347 K | 532 K | 760 K | 1.01 M | 1.27 M | 1.5 M | 1.71 M | 2.22 M | 78 K | 87 K | 96 K | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 107 K | 107 K | 107 K | 1.5 M | - | - | - | - | - | - | 21.1 M | 23.1 M | 25.1 M | 25.1 M | 25.1 M | 25.1 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 8.87 M | 8.87 M | 8.87 M | 8.87 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 26.7 M | 26.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
5.56 M | 7 M | 8.07 M | 9.07 M | 13.7 M | 8.02 M | 9.46 M | 8.24 M | 8.56 M | 12.7 M | 19 M | 28.1 M | 25.1 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 8.56 M | 8.56 M | 8.56 M | 8.56 M | 34.4 M | 34.4 M | 34.4 M | 34.4 M | 34 M | 34 M | 34 M | 34 M | 26.8 M | 26.8 M | 26.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | 63 K | 63 K | 8 K | 8 K | 8 K | 8 K | 42 K | 42 K | 42 K | 42 K | 96 K | 316 K | 470 K | 571 K | 1 M | 626 K | 1 M | 1 M | 740 K | 740 K | 740 K | 740 K | 1.01 M | 1.01 M | 1.01 M | 1.01 M | 830 K | 830 K | 830 K | 830 K | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-274 M | -272 M | -269 M | -266 M | -267 M | -258 M | -254 M | -251 M | -247 M | -226 M | -217 M | -215 M | -210 M | -212 M | -212 M | -212 M | -212 M | -207 M | -207 M | -207 M | -207 M | -178 M | -178 M | -178 M | -178 M | -167 M | -167 M | -167 M | -167 M | -152 M | -152 M | -152 M | -152 M | -132 M | -132 M | -132 M | -132 M | -114 M | -114 M | -114 M | -114 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
16 M | 19.7 M | 23.5 M | 26.8 M | 30.4 M | 28.9 M | 34.5 M | 35 M | 38.8 M | 43.9 M | 59.2 M | 70.8 M | 70.8 M | 47.3 M | 47.3 M | 47.3 M | 47.3 M | 32.6 M | 32.6 M | 32.6 M | 32.6 M | 24 M | 24 M | 24 M | 24 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 56.6 M | 56.6 M | 56.6 M | 56.6 M | 74.2 M | 74.2 M | 74.2 M | 74.2 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
3.32 M | 6.52 M | 10.6 M | 13.5 M | 23 M | 20.6 M | 22.7 M | 21.2 M | 24.6 M | 28.7 M | 35.5 M | 44 M | 32.8 M | 14 M | 14 M | 14 M | 14 M | 8.42 M | 8.42 M | 8.42 M | 8.42 M | 12 M | 12 M | 12 M | 12 M | 9.12 M | 9.12 M | 9.12 M | 9.12 M | 2.01 M | 2.01 M | 2.01 M | 2.01 M | 24 M | 24 M | 24 M | 24 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 2.84 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
10.5 M | 12.7 M | 15.4 M | 17.7 M | 16.7 M | 20.9 M | 25 M | 26.8 M | 30.2 M | 31.2 M | 40.2 M | 42.7 M | 45.7 M | 28.6 M | 28.6 M | 28.6 M | 28.6 M | 8.33 M | 8.33 M | 8.33 M | 8.33 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 8.01 M | 8.01 M | 8.01 M | 8.01 M | 22.2 M | 22.2 M | 22.2 M | 22.2 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | -1.88 M | -1.88 M | -1.88 M | 24.9 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
10.6 M | 12.8 M | 15.5 M | 17.9 M | 16.7 M | 21 M | 25 M | 26.8 M | 30.2 M | 31.1 M | 40.2 M | 42.7 M | 45.7 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 8.01 M | 8.01 M | 8.01 M | 8.01 M | 22.2 M | 22.2 M | 22.2 M | 22.2 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | -84.8 M | -84.8 M | -84.8 M | -84.8 M | -17.3 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency